Menopause Health Center
This article is from the WebMD News Archive
HRT May Reduce Diabetes Risk
Jan. 6, 2003 -- Despite the negative news about hormone replacement therapy (HRT) in recent months, new research suggests that HRT may provide a significant benefit in helping some women reduce their risk of diabetes. But even the study researchers say it's still too early to make any recommendations about using HRT as a tool to prevent type 2 diabetes.
The study, published in the Jan. 7 issue of Annals of Internal Medicine, found that postmenopausal women with heart disease who took a combination of estrogen and progestin (Prempro) had a 35% lower risk of developing diabetes than those who took a placebo. The women on HRT also had more normal fasting blood sugar levels, which when high suggest the likely onset of diabetes. Wyeth-Ayerst, the manufacturer of Prempro, sponsored the study.
Researchers say it's the first such benefit found in a large number of women -- based on more than 2,700 postmenopausal women with heart disease who were followed for about four years. But other results from this same study, as well as another major study known as the Women's Health Initiative (WHI) published in July 2002, show that postmenopausal women on HRT -- combination estrogen and progestin -- face a higher risk of heart disease and breast cancer.
That's why experts, including Eugene Barrett, MD, president-elect of the American Diabetes Association, say this study doesn't provide a reason to change recommendations for HRT, considering increased heart disease risks found by the same study.
Barrett says that until now there really hasn't been much information on the role of HRT in the development of diabetes, and this study raises some interesting questions.
"It gives us a clue that there is something about the biology of estrogen that influences diabetes," says Barrett. But he says that's a matter for clinical research and shouldn't be a factor for most women considering HRT.
Study researcher Alka M. Kanaya, MD, assistant professor of medicine at the University of California, San Francisco, says it's also hard to know whether these findings would apply to other postmenopausal women without heart disease, and that issue will be looked at in larger clinical trials.
"These findings are scientifically interesting, but they need confirmation by further studies," says Kanaya. "It is premature to recommend the use of hormone replacement therapy for the prevention of diabetes."
Karen E. Friday, MD, associate professor of medicine at Tulane University, agrees that further studies are needed and says her great hope is that the negative press about HRT in recent months has not halted research on estrogens because there is more that we need to know.
According to Friday, both animal and human studies suggest that estrogen plays a significant role in how the body regulates the sugar glucose, and she says we don't yet understand all of the potential mechanisms and influences of various forms of estrogen on diabetes.
VIVELLE-DOT (estradiol transdermal system) IS AVAILABLE BY PRESCRIPTION ONLY.
INDICATION
Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman's ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.
IMPORTANT SAFETY INFORMATION
Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).
Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.
The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.
You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information for Vivelle-Dot.
ENABLEX is a prescription medicine used in adults to treat the following symptoms due to a condition called overactive bladder:
- · having a strong need to go to the bathroom right away (also called "urgency")
- · leaks or wetting accidents (also called "urinary incontinence")
- · having to go to the bathroom too often (also called "urinary frequency")
IMPORTANT SAFETY INFORMATION
You should not take once-daily ENABLEX if you have certain types of stomach problems, glaucoma, or have trouble emptying your bladder. Side effects of ENBLEX include blurred vision, and more commonly dry mouth, constipation, indigestion, and abdominal pain. Use caution when doing certain activities until you know how ENBALEX affects you.


